Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07693738 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis

StatusRecruiting
PhasePhase 1
Started2026-05-18
View on ClinicalTrials.gov ↗

Amendment history

2026-07-08
Study Status, Eligibility v1
2026-07-03
Original filing
The purpose of this Phase 1 study is to evaluate the safety and tolerability of a new investigational drug called SSGJ-716 in healthy adults and in participants with moderate-to-severe atopic dermatitis (AD). The study has two parts. The first part (Single Ascending Dose, SAD) will enroll healthy adults.The second part (Multiple Ascending Dose, MAD) will enroll participants with moderate-to-severe AD.
Trial Details
NCT Number NCT07693738
Lead Sponsor Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions AD
Enrollment 96 participants
Start Date 2026-05-18
Primary Completion 2027-08-29 (estimated)
Study Completion 2028-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-10